Targeting ABL and SRC kinases in chronic myeloid leukemia: Experience with dasatinib

Future Oncology

Volumn 2, Issue 6, 2006, Pages 655-665

  Quintás Cardama, Alfonso ^a   Kantarjian, Hagop ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

BCR ABL; Chronic myeloid leukemia; Dasatinib; Resistance; SRC; Tyrosine kinase inhibitor

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ABELSON KINASE; ALPHA INTERFERON; CYTARABINE; DASATINIB; DIURETIC AGENT; IMATINIB; NILOTINIB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; STEROID;

ARTICLE; BONE MARROW SUPPRESSION; CANCER INCIDENCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RESPONSE; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLUID RETENTION; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; IC 50; LEUKEMOGENESIS; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; NONHUMAN; PERIPHERAL EDEMA; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA EFFUSION; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIDE EFFECT; THORACOCENTESIS; THROMBOCYTOPENIA; VOMITING; WEIGHT GAIN;

DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SRC-FAMILY KINASES; THIAZOLES;

EID: 33845614329     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.2.6.655     Document Type: Article

References (62)

1. Jemal A, Tiwari RC, Murray T et al.: Cancer statistics, 2004. CA Cancer J. Clin. 54(1), 8-29 (2004).
2. Bizzozero OJ Jr, Johnson KG, Ciocco A, Kawasaki S, Toyoda S: Radiation-related leukemia in Hiroshima and Nagasaki 1946-1964. II. Ann. Intern. Med. 66(3), 522-530 (1967).
3. Sokal JE, Baccarani M, Russo D, Tura S: Staging and prognosis in chronic myelogenous leukemia. Semin. Hematol. 25(1), 49-61 (1988).
4. Sokal JE, Baccarani M, Tura S et al.: Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood 66(6), 1352-1357 (1985).
5. Nowell P. Hungerford D: A minute chromosome in human chronic granulocytic leukemia. Science 132, 1497 (1960).
6. Rowley J: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243, 290-293 (1973).
7. Deininger MW, Goldman JM, Melo JV: The molecular biology of chronic myeloid leukemia. Blood 96(10), 3343-3356 (2000).
8. Kantarjian HM, Smith TL, O'Brien S et al.: Prolonged survival in chronic myelogenous leukemia after cytogeneric response to interferon-α therapy. The Leukemia Service. Ann. Intern. Med 122(4), 254-261 (1995).
9. Druker BJ, Tamura S, Buchdunger E et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 561-566 (1996).
10. Beran M, Cao X, Estrov Z et al. Selective inhibition of cell proliferation and Bcr-Abl phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 Bcr-Abl protein by a tyrosine kinase inhibitor (CGP-57148). Clin. Cancer Res. 1661-1672 (1998).
11. + leukemic cells and induces apoptosis. Blood Cells Mol. Dis. 23(3), 380-394 (1997).
12. O'Brien SG, Guilhot F, Larson RA et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348(11), 994-1004 (2003).
13. Druker B, Guilhot F, O'Brien S. et al.: Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): the 5-year update from the IRIS study. Proc. Am. Soc. Clin. Oncol. 24(18S) (2006) (Abstract 6506).
14. Hochhaus A, La Rosee P: Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 18(8), 1321-1331 (2004).
15. O'Hare T, Walters DK, Stoffregen EP et al.: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 65(11), 4500-4505 (2005).
16. Deininger M, Buchdunger E, Druker BJ: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105(7), 2640-2653 (2005).
17. Carter TA, Wodicka LM, Shah NP et al.: Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl. Acad. Sci. USA 102(31), 11011-11016 (2005).
18. Daley GQ, van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia in mice by die P210bcr/abl gene of the Philadelphia chromosome. Science 247(4944), 824-830 (1990).
19. Ramaraj P. Singh H, Niu N et al.: Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors. Cancer Res. 64(15), 5322-5331 (2004).
20. + cells with a BCR/ABL-containing retroviral vector. Blood 97(8), 2406-2412 (2001).
21. Kelliher MA. McLaughlin J, Witte ON, Rosenberg N: Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl. Acad. Sci. USA 87(17), 6649-M53 (1990).
22. Pendergast AM, Gishizky ML, Havlik MH, Witte ON: SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence. Mol Cell Biol. 13(3), 1728-1736 (1993).
23. 2,-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by BCR-ABL. Mol. Cell Biol. 21(3), 840-853 (2001).
24. Ren R: Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer 5(3), 172-183 (2005).
25. Pendergast AM, Quilliam LA, Cripe LD et al.: BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75(1), 175-185 (1993).
26. Hu Y, Liu Y, Pelletier S et al.: Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nature Genet. 36(5), 453-461 (2004).
27. Bhatia R, Holtz M, Niu N et al.: Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101 (12), 4701-4707 (2003).
28. Kerkhoff E, Rapp UR: Cell cycle targets of Ras/Raf signalling. Oncogene 17(11 Reviews), 1457-1462 (1998).
29. Tetsuya N, Kazuhide M et al.: STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J. 18, 4754-4765 (1999).
30. Abram CL, Courtneidge SA. Src family tyrosine kinases and growth factor signaling. Exp. Cell Res. 254(1), 1-13 (2000).
31. Stanglmaier M, Warmuth M, Kleinlein I, Reis S, Halleck M: The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains. Leukemia 17(2), 283-289 (2003).
32. Danhausrr-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hallek M: Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res. 56(15), 3589-3596(1996).
33. Warmuth M, Bergmann M, Priess A et al.: The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J. Biol. Chem. 272(52), 33260-33270 (1997).
34. Dai Y, Rahmani M, Corey SJ, Dent P, Grant S: A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J. Biol. Chem. 279(33), 34227-34239 (2004).
35. Donato NJ, Wu JY, S tapley J et al.: BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to ST1571. Blood 101(2), 690-698 (2003).
36. Donato NJ, Wu JY, Stapley J et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 64(2), 672-677 (2004).
37. Hoffmann WK, de Vos S, Elashoff D. et al.: Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor ST1571 and gene-expression profiles: a gene-expression study. Lancet 359(9305), 481-486 (2002).
38. Schindler T, Bornmann W, Pellicena P et al., Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289(5486), 1938-1942 (2000).
39. Nagar B, Bornmann WG, Pellicena P et al.: Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62(15), 4236-4243 (2002).
40. Lombardo LJ, Lee FY, Chen P et al. Discovery of N-(2-chloro-6-methyl-phenyl)- 2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)- 2-methylpyrimidin-4-ylamino)thiazole- 5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47(27), 6658-6661 (2004).
41. Tokarski JS, Newitt JA, Chang CY et al.: The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 66(11), 5790-5797 (2006).
42. Lee F, Lombardo L, Camuso A et al.: BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad spectrum anti-tumor activities in vitro and in vivo. Proc. Am. Assoc. Cancer Res. 46, 159 (2005) (Abstract 675).
43. Shah NP, Tran C, Lee FY et al.: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305(5682), 399-401 (2004).
44. Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL: Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc. Natl. Acad. Sci. USA 102(9), 3395-3400 (2005).
45. Bradeen HA, Eide CA, O'Hare T et al: Comparison of imatinib, dasatinib (BMS-354825), and nilotinib (AMN107) in an n-ethyl-n-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108(7), 2332-2338 (2006).
46. Hughes TP, Kaeda J, Branford S et al.: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349(15), 1423-1432 (2003).
47. Graham S, Jorgensen HG, Allan E et al.: Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to ST1571 in vitro. Blood 99, 319-325 (2002).
48. Holtz MS, Slovak ML, Zhang F et al.: Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 99(10), 3792-3800 (2002).
49. Copland M, Hamilton A, Elrick LJ et al.: Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML, but does not eliminate the quiescent fraction. Blood 107(11), 4532-4539(2006).
50. + cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 105(5), 2093-2098 (2005).
51. Lee F, Wen ML, Camuso A et al.: Quiescent chronic myelogenous leukemia (CML) cells are resistant to BCR-ABL inhibitors but preferentially sensitive to BMS-214662, a farnesyltransferase inhibitor (FTI) with unique quiescent-cell selective cytotoxicity. Blood 106(11) (Abstract 1993) (2005).
52. Gao H, Lee BN, Talpaz M et al.: Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia 1901), 1905-1911 (2005)
53. Gao H, Talpaz M, Lee N et al.: BMS-354825 induced complete hematologic remission in chronic phase CML patients without affecting T-cell cytokine production. J. Clin. Oncol. 23, S589 (Abstract 6619) (2005).
54. Talpaz M, Shah NP, Kantarjian H et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354(24), 2531-2541 (2006).
55. Talpaz M, Kantarjian HM, Paquette R et al.: A Phase I study of BMS-354825 in patients with imatinib-resistant and intolerant chronic phase chronic myeloid, leukemia (CML): Results from CA180002. Proc. Am. Soc. Clin. Oncol. 23, S564 (2005) (Abstract 6519).
56. Hochhaus A, Kantarjian H, Baccarini M et al.: Dasatinib efficacy and safety in patients with chronic phase CML resistant or intolerant to imatinib: results of the CA180013 'START-C' Phase II study. Proc. Am. Soc. Clin. Oncol. 24(18S)(2006) (Abstract 6508).
57. Talpaz M, ApperleY JF, Kim DW et al.: Dasatinib Phase II study in patients with accelerated phase chronic myeloid leukemia (CML) who are resistant or intolerant to imatinib: results of the CA180005 'START-A' study. Proc. Am. Soc. Clin. Oncol. 24(18S) (2006) (Abstract 6526).
58. Cortes J, Kim DW, Rosti G. et al: Dasatinib (D) in patients (pts) with chronic myelogenous leukemia (CML) in myeloid blast crisis (MBC) who are imatinib-resistant (IM-R) or IM-intolerant IM-I): Results of the CA180006 'START-B' study. Proc. Am. Soc. Clin. Oncol. 24(18S) (2006) (Abstract 6529).
59. Coutre S, Martinelli G, Dombret H et al: Dasatanib (D) in patients (pts) with chronic myelogenous leukemia (CML) in lymphoid blast crisis (LB-CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are imatinib (IM)-resistant (IM-R) or intolerant (IM-I): The CA180015 'START-E' study. Proc. Am. Soc. Clin. Oncol. 24(18S) (2006) (Abstract 6528).
60. Shah N, Rousselot P, Pasquini R et al.: Dasatinib (D) vs high dose imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib. Results of CA180017 'START-R' randomized trial. Proc. Am. Soc. Clin. Oncol. 24(18S) (2006) (Abstract 6507).
61. Branford S, Hughes T, Nicoll J et al.: Major molecular responses to dasatinib (BMS-354825) are observed in imatinib-resistant late stage chronic and advanced CML patients: impact and fate of imatinib-resistant clones in dasatinib-treated patients. Blood 106(11) (2005) (Abstract 437).
62. Quintas-Cardama A, Kantarjian H, Jones D et al.: Dynamics of molecular response to dasatinib (BMS-354825) in patients (pts) with chronic myelogenous leukemia (CML) resistant or intolerant to imatinib. Proc. Am. Soc. Clin. Oncol 24(18S) (2006) (Abstract 6525).